Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CF

Summary

This study will determine the safety, tolerability, and pharmacokinetics of a single dose of GS-5737 administered with a 2.8% saline solution vehicle in adult subjects with CF.

Timeline

Start

2013-05

Primary completion

2013-07

Completion

2013-08

Drugs

Indications